However, several in vitro preclinical studies targeting the IL-6 signaling pathway, including antibodies against IL-6 and IL-6 receptors (CNTO328), IL-6 antisense oligonucleotides and IL-6 super antagonist Sant7, were unsuccessful due to autocrine IL-6 production, and/or activation of the IL-6/STAT3 and NF-κB pathways following MM cells-BM stromal cells interactions [19]. The gene discussed is STAT3; the disease is Miyoshi myopathy.